|
|
|
 |
FDA Approval Activities for this Drug…
Norvir (Ritonavir) Capsules & Solution, Abbott 20-659/S-030 & 20-945/S-013 9/10/03 9/25/03 9/25/03 Norvir (Ritonavir) Abbott 20-659/S-027 & 20-945/S-008 3/14/02 3/29/02 3/14/02 Norvir (Ritonavir) Abbott 20-659/S-026 & 20-945/S-007 3/6/01 4/26/01 Norvir (ritonavir capsules) Soft Gelatin (ritonavir), Abbott 20-659/S-025 20-945/S-005 08/21/01 4/25/03 Norvir (Ritonavir) Abbott 20-650/S-013 & 20-680/S-011 5/26/99 Norvir Indications:Protease inhibitor that is indicated, in combination with other antiretroviral agents, for the treatment of HIV-1 infection. Norvir (Ritonavir) Abbott 20-945 6/29/99 Norvir Indications: A protease inhibitor that is indicated, in combination with other antiretroviral agents, for the treatment of HIV-1 infection. Kaletra (lopinavir/ritonavir) Abbott Laboratories | NORVIR (ritonavir) capsules, Abbott Labs, Labeling Revision | NORVIR (ritonavir) oral solution, Abbott Labs, Labeling Revision | KALETRA (lopinavir/ritonavir) capsules, Abbott Labs, Labeling Revision | KALETRA (lopinavir/ritonavir) oral solution, Abbott Labs, Labeling Revision | KALETRA (lopinavir/ritonavir) capsules, Abbott Labs, New Dosage Regimen | NORVIR (ritonavir) oral solution, Abbott Labs, Patient Population Altered | NORVIR (ritonavir) soft gelatin capsules, Abbott Labs, Patient Population Altered | KALETRA (lopinavir/ritonavir) tablets, Abbott Labs, Approval | NOVIR (ritonavir) capsules, Abbott Labs, Labeling Revision | NOVIR (ritonavir) oral solution, Abbott Labs, Labeling Revision | KALETRA (lopinavir/ritonavir) tablet, Abbott Labs, Labeling Revision | KALETRA (lopinavir/ritonavir) oral solution, Abbott Labs, Labeling Revision | KALETRA (lopinavir/ritonavir) capsules, Abbott Labs, Labeling Revision | Kaletra (lopinavir/ritonavir) Oral Solution, Abbott Labs, Labeling Revision | Kaletra (lopinavir/ritonavir) Tablets, Abbott Labs, Labeling Revision
|